HK1079705A1 - 包含用於治療癌症及感染性疾病的熱休克蛋白或α2-巨球蛋白的組合物製備方法 - Google Patents

包含用於治療癌症及感染性疾病的熱休克蛋白或α2-巨球蛋白的組合物製備方法

Info

Publication number
HK1079705A1
HK1079705A1 HK05112097.2A HK05112097A HK1079705A1 HK 1079705 A1 HK1079705 A1 HK 1079705A1 HK 05112097 A HK05112097 A HK 05112097A HK 1079705 A1 HK1079705 A1 HK 1079705A1
Authority
HK
Hong Kong
Prior art keywords
macroglobulin
cancer
alpha
useful
treatment
Prior art date
Application number
HK05112097.2A
Other languages
English (en)
Inventor
Pramod K Srivastava
Original Assignee
Univ Of Connecticut Health Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Connecticut Health Center filed Critical Univ Of Connecticut Health Center
Publication of HK1079705A1 publication Critical patent/HK1079705A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK05112097.2A 2001-08-20 2005-12-29 包含用於治療癌症及感染性疾病的熱休克蛋白或α2-巨球蛋白的組合物製備方法 HK1079705A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31362901P 2001-08-20 2001-08-20
US33722201P 2001-12-06 2001-12-06
PCT/US2002/026573 WO2003015712A2 (en) 2001-08-20 2002-08-20 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin

Publications (1)

Publication Number Publication Date
HK1079705A1 true HK1079705A1 (zh) 2006-04-13

Family

ID=26978972

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05112097.2A HK1079705A1 (zh) 2001-08-20 2005-12-29 包含用於治療癌症及感染性疾病的熱休克蛋白或α2-巨球蛋白的組合物製備方法

Country Status (12)

Country Link
US (1) US7666581B2 (zh)
EP (1) EP1536829A4 (zh)
JP (1) JP4384489B2 (zh)
KR (1) KR20040064688A (zh)
CN (1) CN1635896A (zh)
AU (1) AU2002335654B2 (zh)
CA (1) CA2457008A1 (zh)
HK (1) HK1079705A1 (zh)
IL (1) IL160511A0 (zh)
PL (1) PL375043A1 (zh)
RU (2) RU2335295C2 (zh)
WO (1) WO2003015712A2 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
EP1603391A4 (en) * 2003-02-20 2009-06-24 Univ Connecticut Health Ct METHOD OF USE OF COMPOSITIONS COMPRISING HIGH SHOCK PROTEINS OR ALPHA-2-MACROGLOBULIN IN THE TREATMENT OF CANCER AND INFECTION DISEASES
WO2004074454A2 (en) * 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
WO2005120558A2 (en) * 2004-05-25 2005-12-22 University Of Connecticut Health Center Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
US8754094B2 (en) * 2007-08-15 2014-06-17 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
HUE025852T2 (en) 2008-06-26 2016-04-28 Orphazyme Aps Use of HSP70 to regulate enzyme activity
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
US10265388B2 (en) 2012-02-21 2019-04-23 Cytonics Corporation Systems, compositions, and methods for transplantation
CN103372209B (zh) * 2012-04-24 2014-09-17 中国科学院微生物研究所 gp96蛋白的抗体在制备癌细胞抑制剂中的应用
PL3193840T3 (pl) 2014-09-15 2021-12-06 Orphazyme A/S Preparat arimoklomolu
ES2845727T3 (es) * 2015-02-06 2021-07-27 Heat Biologics Inc Vector que coexpresa una vacuna y moléculas coestimuladoras
MA42420A (fr) 2015-05-13 2018-05-23 Agenus Inc Vaccins pour le traitement et la prévention du cancer
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
RS61291B1 (sr) 2016-04-29 2021-02-26 Orphazyme As Arimoklomol za lečenje poremećaja povezanih sa glukocerebrozidazom
RU2640017C1 (ru) * 2016-10-31 2017-12-25 Алла Анатольевна Ляшенко Способ получения биологического материала для создания аутологичных противоопухолевых вакцин
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
MX2023005954A (es) 2020-11-19 2023-09-04 Zevra Denmark As Procesos para preparar citrato de arimoclomol e intermediarios del mismo.

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US192230A (en) * 1877-06-19 Improvement in ironing-tables
US211971A (en) * 1879-02-04 Improvement in centrifugal drying-machines
US172682A (en) * 1876-01-25 Improvement in tool-carrier attachments to screw-machines
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US28207A (en) * 1860-05-08 Alfred b
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
DE68924162T2 (de) 1988-06-15 1996-04-25 Medical Res Council Stressproteine und verwendungen dafür.
WO1990002564A1 (en) 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) 1990-07-25 1990-09-12 Burnie James P Medicaments
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
AU660430B2 (en) 1990-11-08 1995-06-29 Stanford Rook Limited Mycobacterium as adjuvant for antigens
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
WO1993024136A1 (en) 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
GB9200949D0 (en) 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
FR2688227A1 (fr) 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2130089A1 (en) 1992-03-09 1993-09-16 Aldo Mancini Protein compound, coding nucleotide sequences, producing cell line and uses thereof
EP0636248A4 (en) 1992-04-14 1996-11-13 Univ Duke METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
WO1994014976A1 (en) 1992-12-18 1994-07-07 Duke University Immune response modulator complex, and uses thereof
US5496934A (en) * 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
PT700445E (pt) 1993-06-04 2002-07-31 Whitehead Biomedical Inst Proteinas de stress e suas utilizacoes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
CA2229543A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
CA2231998A1 (en) * 1995-09-13 1997-03-20 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5891653A (en) * 1995-12-29 1999-04-06 Attfield; Derrick Cecil Method of suppressing graft rejection by means of stress proteins
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
DE19602985A1 (de) 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
EP0954601A4 (en) * 1996-03-20 2004-08-18 Genzyme Corp METHOD FOR DETECTING CYTOTOXIC T-CELL EPITOPES
CA2265935C (en) * 1996-09-20 2006-09-05 The University Of New Mexico Heat shock protein complexes
US5747332A (en) * 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US5947646A (en) * 1997-02-25 1999-09-07 Guardian Fiberglass, Inc. System for blowing loose-fill insulation
US6709672B2 (en) * 1997-03-05 2004-03-23 Biotech Tools S.A. Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
BE1011033A6 (fr) * 1997-03-05 1999-04-06 Univ Bruxelles Composition pharmaceutique et/ou alimentaire pour le traitement de pathologies liees a un rejet de greffe, une reaction allergique ou auto-immune ou du cancer.
US6545137B1 (en) 1997-04-15 2003-04-08 John A. Todd Receptor
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6403092B1 (en) * 1998-04-01 2002-06-11 Duke University Immune response modulator alpha-2 macroglobulin complex
US6797480B1 (en) * 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6730302B1 (en) * 1998-11-24 2004-05-04 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kD heat shock protein
JP2002539174A (ja) 1999-03-17 2002-11-19 エントレメッド インコーポレイテッド 癌および血管新生関連の疾病の治療のためのｌｄｌ様受容体リガンドを使用する組成物および方法
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
AU6669401A (en) 2000-06-02 2001-12-11 Univ Connecticut Health Ct Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
WO2002011669A2 (en) * 2000-08-07 2002-02-14 Antigenics, Llc Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
AU2001286775A1 (en) 2000-08-25 2002-03-04 Duke University Adjuvant
CA2422718A1 (en) 2000-09-15 2002-04-18 University Of Connecticut Health Center Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
AU2001292674A1 (en) 2000-09-15 2002-04-29 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
US20020172682A1 (en) 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US20030211971A1 (en) 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
RU2376029C2 (ru) 2002-04-25 2009-12-20 Юниверсити Оф Коннектикут Хелт Сентер Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия
CA2485098A1 (en) 2002-05-02 2003-11-13 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
EP1603391A4 (en) 2003-02-20 2009-06-24 Univ Connecticut Health Ct METHOD OF USE OF COMPOSITIONS COMPRISING HIGH SHOCK PROTEINS OR ALPHA-2-MACROGLOBULIN IN THE TREATMENT OF CANCER AND INFECTION DISEASES

Also Published As

Publication number Publication date
CN1635896A (zh) 2005-07-06
RU2004108129A (ru) 2005-04-20
AU2002335654B2 (en) 2008-02-21
WO2003015712A3 (en) 2005-04-14
PL375043A1 (en) 2005-11-14
RU2335295C2 (ru) 2008-10-10
JP4384489B2 (ja) 2009-12-16
JP2005511495A (ja) 2005-04-28
CA2457008A1 (en) 2003-02-27
IL160511A0 (en) 2004-07-25
US20030129196A1 (en) 2003-07-10
WO2003015712A2 (en) 2003-02-27
EP1536829A4 (en) 2006-05-31
RU2008120299A (ru) 2009-11-27
KR20040064688A (ko) 2004-07-19
EP1536829A2 (en) 2005-06-08
US7666581B2 (en) 2010-02-23

Similar Documents

Publication Publication Date Title
HK1079705A1 (zh) 包含用於治療癌症及感染性疾病的熱休克蛋白或α2-巨球蛋白的組合物製備方法
EP1603391A4 (en) METHOD OF USE OF COMPOSITIONS COMPRISING HIGH SHOCK PROTEINS OR ALPHA-2-MACROGLOBULIN IN THE TREATMENT OF CANCER AND INFECTION DISEASES
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL161070A0 (en) Compositions for the treatment of infectious diseases
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
EP1453536A4 (en) COMPOSITION FOR PRESERVING VIRUSES
SI1757606T1 (sl) Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
DE60208794D1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
EP1421185A4 (en) FAST TIE TEMPERATURE PRESSURE STERILIZATION AND VACCINE MANUFACTURING
AU2002312303A1 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
SG113427A1 (en) Heat treatment of titanium-alloy article having martensitic structure
PL368935A1 (en) Methods of treating pulmonary disease
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
EP1461047A4 (en) COMPOSITIONS AND METHODS FOR TREATING ANIMALS
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1472273A4 (en) COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES
EP1435996A4 (en) COMPOSITIONS COMPRISING MIXTURES OF THERAPEUTIC PROTEINS AND METHODS OF PREPARATION THEREOF
ITMI20010100U1 (it) Chiodo endomidollare per l'osteosintesi delle fratture troncanterichedel femore
EP1440080A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CELLULAR PROLIFERATION DISORDERS INVOLVING THE 20750
GB0105606D0 (en) Immunogens and vaccines and their preparation and use
AU2002342188A8 (en) Methods and compositions for treating flavivirus-mediated disease
GB0100092D0 (en) Treatment of degenerative diseases
GB0128628D0 (en) Disease treatment
AU2002353915A1 (en) Methods and compositions for treating rotavirus-mediated disease